Capricor Therapeutics Faces Class Action Lawsuit Over Alleged Securities Fraud and Investor Losses

Reuters

2025/09/05

Capricor <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Faces Class Action Lawsuit Over Alleged Securities Fraud and Investor Losses

Capricor Therapeutics Inc. is facing a class action securities lawsuit filed on behalf of investors who suffered financial losses due to alleged securities fraud. The lawsuit covers the period between October 9, 2024, and July 10, 2025, during which Capricor allegedly misled investors about the efficacy and safety of its lead cell therapy candidate, deramiocel, for treating cardiomyopathy associated with Duchenne muscular dystrophy. The company reportedly provided false and misleading statements concerning the drug's Phase 2 HOPE-2 trial data and its potential to secure a Biologics License Application from the FDA. Following the FDA's issuance of a Complete Response Letter denying the BLA, citing insufficient evidence of effectiveness and unresolved issues in the manufacturing section, Capricor's stock price sharply declined. The law firm Levi & Korsinsky, LLP, known for its expertise in securities litigation, is representing the affected shareholders in this legal action.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capricor Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1069246) on September 05, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎国际,美股交易,港股交易,交易美股,股票信息,股价,美股行情,美股打新,港股打新,IPO打新,购买美股,全球投资","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2565550853"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2565550853\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2565550853?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-05 19:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2565550853","market":"nz","top_or_hot":-1,"title":"Capricor Therapeutics Faces Class Action Lawsuit Over Alleged Securities Fraud and Investor Losses","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Capricor <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Faces Class Action Lawsuit Over Alleged Securities Fraud and Investor Losses\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CAPR\">Capricor Therapeutics Inc</a>. is facing a class action securities lawsuit filed on behalf of investors who suffered financial losses due to alleged securities fraud. The lawsuit covers the period between October 9, 2024, and July 10, 2025, during which Capricor allegedly misled investors about the efficacy and safety of its lead cell therapy candidate, deramiocel, for treating cardiomyopathy associated with Duchenne muscular dystrophy. The company reportedly provided false and misleading statements concerning the drug's Phase 2 HOPE-2 trial data and its potential to secure a Biologics License Application from the FDA. Following the FDA's issuance of a Complete Response Letter denying the BLA, citing insufficient evidence of effectiveness and unresolved issues in the manufacturing section, Capricor's stock price sharply declined. The law firm Levi &amp; Korsinsky, LLP, known for its expertise in securities litigation, is representing the affected shareholders in this legal action.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capricor Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1069246) on September 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Capricor Therapeutics Faces Class Action Lawsuit Over Alleged Securities Fraud and Investor Losses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCapricor Therapeutics Faces Class Action Lawsuit Over Alleged Securities Fraud and Investor Losses\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-05 19:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Capricor <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Faces Class Action Lawsuit Over Alleged Securities Fraud and Investor Losses\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CAPR\">Capricor Therapeutics Inc</a>. is facing a class action securities lawsuit filed on behalf of investors who suffered financial losses due to alleged securities fraud. The lawsuit covers the period between October 9, 2024, and July 10, 2025, during which Capricor allegedly misled investors about the efficacy and safety of its lead cell therapy candidate, deramiocel, for treating cardiomyopathy associated with Duchenne muscular dystrophy. The company reportedly provided false and misleading statements concerning the drug's Phase 2 HOPE-2 trial data and its potential to secure a Biologics License Application from the FDA. Following the FDA's issuance of a Complete Response Letter denying the BLA, citing insufficient evidence of effectiveness and unresolved issues in the manufacturing section, Capricor's stock price sharply declined. The law firm Levi &amp; Korsinsky, LLP, known for its expertise in securities litigation, is representing the affected shareholders in this legal action.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capricor Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1069246) on September 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250905:nNDL6VV7J4:1","article_id":"2565550853","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2565550853","pubTimestamp":1757072836,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Capricor Therapeutics Inc. is facing a class action securities lawsuit filed on behalf of investors who suffered financial losses due to alleged securities fraud. The lawsuit covers the period between October 9, 2024, and July 10, 2025, during which Capricor allegedly misled investors about the efficacy and safety of its lead cell therapy candidate, deramiocel, for treating cardiomyopathy associated with Duchenne muscular dystrophy. The company reportedly provided false and misleading statements concerning the drug's Phase 2 HOPE-2 trial data and its potential to secure a Biologics License Application from the FDA. Following the FDA's issuance of a Complete Response Letter denying the BLA, citing insufficient evidence of effectiveness and unresolved issues in the manufacturing section, Capricor's stock price sharply declined. The law firm Levi & Korsinsky, LLP, known for its expertise in securities litigation, is representing the affected shareholders in this legal action.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CAPR":"Capricor Therapeutics Inc"},"translate_title":"Capricor Therapeutics因涉嫌证券欺诈和投资者损失面临集体诉讼","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAPR":0.9},"content_text":"Capricor Therapeutics Faces Class Action Lawsuit Over Alleged Securities Fraud and Investor Losses\n    \n\nCapricor Therapeutics Inc. is facing a class action securities lawsuit filed on behalf of investors who suffered financial losses due to alleged securities fraud. The lawsuit covers the period between October 9, 2024, and July 10, 2025, during which Capricor allegedly misled investors about the efficacy and safety of its lead cell therapy candidate, deramiocel, for treating cardiomyopathy associated with Duchenne muscular dystrophy. The company reportedly provided false and misleading statements concerning the drug's Phase 2 HOPE-2 trial data and its potential to secure a Biologics License Application from the FDA. Following the FDA's issuance of a Complete Response Letter denying the BLA, citing insufficient evidence of effectiveness and unresolved issues in the manufacturing section, Capricor's stock price sharply declined. The law firm Levi & Korsinsky, LLP, known for its expertise in securities litigation, is representing the affected shareholders in this legal action.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capricor Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1069246) on September 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"policyRegulatory,event","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}